I was mostly being snarky, but a few quick points (and I'm by no means a geneticist).
1. In general terms, genetic homogeneity is a bad thing and increases susceptibility to disease. That is why you may hear about certain endogamous populations having high rates of certain diseases (Ashkenazi Jews and tay-sachs disease is a classic example). Right. So certain countries don't have any Ashkenazi Jews, so they are not looking for that. We do, so that is another thing for the US to screen for.
2. The diseases that fall into this category (with specific driver mutations that are highly represented in certain sub-populations) are incredibly rare. It's not like working all day every day on a Honda. It's like working all day every day on lime green 1970 Dodge Coronet Convertibles. Screening and treating these diseases aren't even a rounding error when discussing health care expenditures. But the US doctors still need to be able to recognize those drivers and be able to run those tests if they encounter a potential patient, right? So that need for knowledge and the test adds to the cost.
3. A place like Austria, while less "diverse" than the US, still has an incredible amount of genetic diversity, and we share the common diseases that drive health care spending. In other words, the breadth of diseases that dominate health care dollars is no different. Our doctors are fixing the same Hondas, Toyotas and Fords, and there's no biologic reason we should need more specialists to do so. The driver for specialization in our country is economic, not biologic. But we're not also just treating Austria's common diseases, we are sharing every other country's common diseases as well.